Takeda Pharma announces results from its Phase 3 TOURMALINE-MM2 trial
Category: #health  By Pankaj Singh  Date: 2020-09-11
  • share
  • Twitter
  • Facebook
  • LinkedIn

Takeda Pharma announces results from its Phase 3 TOURMALINE-MM2 trial

Takeda Pharmaceutical Company Ltd, a renowned Japanese pharmaceutical company, has reportedly announced the outcome of Phase 3 TOURMALINE-MM2 trial that assesses the combination of ixazomib (NINLARO) and lenalidomide, dexamethasone versus dexamethasone and lenalidomide with placebo in patients suffering from multiple myeloma and are not eligible to undergo an autologous stem cell transplant.

The data was presented at the SOHO (Society of Hematologic Oncology) virtual scientific meeting held on September 9, 2020. The new trial discovered that adding NINLARO to dexamethasone and lenalidomide led to a 13.5-month rise in the median PFS (progression-free survival). However, the study did not fulfill the statistical significance threshold and also did not meet the PFS primary endpoint.

Lead author and principal investigator of the TOURMALINE-MM2 trial, Thierry Facon, MD, Lille University Hospital stated that there is a particular need in the multiple myeloma patients as presently there are no authorized all-oral treatment options that are proteasome inhibitor based.

Facon further added that results from the Phase 3 trial are crucial for the patient population and throughout multiple subgroups like patients suffering from high-risk cytogenetics. The company expects that the newly found data would help for future research and also progress multiple myeloma community further.

Christopher Arendt, Head of Takeda’s Oncology Therapeutic Unit, stated that the company hopes that the results from the Phase 3 trial would foster constructive conversations and also help drive future research efforts, especially for patients that can greatly benefit from a proteasome inhibitor-based and all-oral combination which helps to preserve the quality of life.

Arendt further added that the company remains committed to working towards the treatment of multiple myeloma community and also looks forward to providing mature data from the company’s ongoing Phase 3 studies related to multiple myeloma maintenance.

Source credit: https://www.businesswire.com/news/home/20200909005113/en/Takeda-Announces-Results-Phase-3-Clinical-Trial



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Dada Group partners with Ferrero for new snack food retail model
Dada Group partners with Ferrero for new snack food retail model
By Pankaj Singh

The new retail model will help Ferrero improve brand reach to younger online customers in China

Chinese on-demand delivery and retail platform, Dada Group has inked...

Aphena Pharma to complete expansion of Solid Dose Division by April
Aphena Pharma to complete expansion of Solid Dose Division by April
By Pankaj Singh

Aphena Pharma Solutions, a pharmaceutical services provider, has reportedly announced the continuous expansion of its Tennessee-based Solid Dose Division worth $21 million. This division is expected to be completed by ...

Canada-based CloudMD buys CMD to expand medical database
Canada-based CloudMD buys CMD to expand medical database
By Pankaj Singh

CloudMD Software & Services Inc., a virtual medical care solutions provider based in Canada, has reportedly announced that it has completed the acquisition of the Canadian Medical Directory (CMD)- the nation’...